Oct 3, 2026 · Sports, Health & Nutrition Daily Digest
A roundup of sports, fitness, wellness, and nutrition news for Oct 3, 2026, with summaries, links, and commentary.
I. Nutrition & Diet
1. Scientific Reports: Four weeks of meals matched to Japanese dietary reference intakes did not beat control on visceral fat or salivary cortisol; lipid and blood-pressure shifts were secondary (Nutrition)
Summary:
Akihito Hishikawa, Kaori Hayashi, Hiroshi Itoh, and colleagues at Keio University, with researchers from Nissin Foods, published an exploratory three-arm, single-blind randomized trial in Scientific Reports on Oct 3, 2026 (UMIN000050103). Three hundred people ate provided meals for four weeks: Opti meals matched to Japanese Dietary Reference Intake macronutrient ratios and 26 micronutrients, a micronutrient-insufficient control, or low-carbohydrate high-fat Opti meals with the same micronutrients. In this partial report, neither primary outcome, visceral fat area or salivary cortisol and melatonin, differed between groups. In prespecified secondary analyses, LDL cholesterol fell in both Opti groups versus control, and systolic pressure fell only in the low-carbohydrate high-fat Opti group. A subgroup of older men had 10 people per arm, and PhenoAge was lower with Opti; a post-hoc model predicted cardiometabolic responders with ROC-AUC 0.71-0.76. Nissin funded the trial and took part in design and meal preparation, and the authors call the secondary findings hypothesis-generating.
Links:
Commentary:
Do not expect a micronutrient-optimized meal kit to shrink visceral fat in four weeks; the cholesterol and blood-pressure changes are not yet a confirmed primary benefit, and a food company paid for the trial.
2. Scientific Reports: A higher alternative Mediterranean diet score tracked with hypertension prevalence at OR 0.71 in US adults, in a cross-sectional analysis (Nutrition)
Summary:
Yuan-feng Zhou of Jiujiang Third People's Hospital, Xiang-Tao Zhang of the Second Affiliated Hospital of Nanchang University, and Huabin He of Jiujiang First People's Hospital published a cross-sectional analysis in Scientific Reports on Oct 3, 2026. Using the US National Health and Nutrition Examination Survey for 2005-2018, they included 23,794 eligible participants and related the alternative Mediterranean diet score (aMED) to prevalent hypertension with multivariable logistic regression. The odds ratio for higher aMED was 0.71 (95% CI 0.61-0.82), and sensitivity analyses pointed the same way. The association was stronger in women, people without diabetes, and people who did not drink alcohol. The survey was conducted under National Center for Health Statistics ethics review, and the authors say prospective studies are still needed before the Mediterranean diet can be credited with a blood-pressure benefit.
Links:
Commentary:
Vegetables, whole grains, beans, fish, and olive oil remain a sensible base for a blood-pressure diet, but 0.71 is a prevalence association, not proof that switching patterns will lower a reading.
II. Exercise & Training Science
3. Scientific Reports: Combined upper- and lower-limb activation did not significantly speed 50 m front crawl in national-level male swimmers (Training)
Summary:
Arkadiusz Stanula, Wojciech Sadowski, Wojciech Rejdych, Marek Strzala, and Katja Weiss published a randomized repeated-measures crossover in Scientific Reports on Oct 3, 2026. Fourteen national-level male swimmers compared control with one combined post-activation condition: lunge-position squats on a Keiser squat machine, then prone butterfly-style double-arm pulls on a Keiser functional trainer, with recovery timed from each swimmer's upper-limb power output. The 50 m front crawl was 25.61±0.81 versus 25.76±0.83 seconds, a difference of −0.157 seconds, p = 0.098, effect size 0.45, favorable in direction but not significant. Reaction time and turn time were shorter, stroke rate rose, and stroke length and stroke index fell, without a gain in free-swimming speed.
Links:
Commentary:
A heavy lower-body plus pulling activation before a race does not guarantee a faster 50 m; recreational swimmers get more from skill work and an easy swim warm-up than from copying this machine routine.
4. BMC Microbiology: Eight weeks of high-intensity interval running changed gut microbiota in senescence-prone mice, with six males per group (Training)
Summary:
Xiang Tang, Pengfei Li, Hongzhi Gao, and Xinlong Ma of Tianjin Medical University published an animal experiment in BMC Microbiology on Oct 3, 2026. Thirty-six male senescence-accelerated SAMP6 mice and 12 senescence-resistant SAMR1 mice were split into eight groups of six. From five months of age, SAMP6 mice ran on a treadmill for eight weeks: low-intensity continuous at 12 m/min, moderate continuous at 15 m/min, high-intensity intervals at 12/20 m/min, or a progression from 12 to 15 m/min. Fecal 16S rRNA sequencing of the V3-V4 region showed higher alpha diversity in age-matched sedentary SAMR1 mice than in sedentary SAMP6 mice. High-intensity intervals restructured the SAMP6 community, enriching Eggerthella lenta and Lactobacillus johnsonii and raising Proteobacteria without lowering alpha diversity; low-intensity continuous training had the lowest diversity. The authors say fecal transplant studies are still needed for causality. Ethics approval was from Tianjin Hospital.
Links:
Commentary:
This is not a reason for older adults to start high-intensity intervals in order to "fix the microbiome"; human dose, fall risk, and metabolic benefit were not tested in this mouse sequencing study.
III. Public Health & Disease Prevention
5. NEJM: Weekly retatrutide produced up to 25.0% weight loss at 80 weeks on the treatment-regimen estimand in adults with obesity and without diabetes; the drug is not approved (Public health)
Summary:
ScienceAlert reported on Oct 3, 2026, on TRIUMPH-1, led by Ania Jastreboff at Yale. The randomized double-blind phase 3 trial assigned 2,339 adults with obesity and without diabetes to weekly subcutaneous retatrutide at 4 mg, 9 mg, or 12 mg, or to placebo, for 80 weeks. The drug activates GLP-1, GIP, and glucagon receptors, and Eli Lilly funded the trial. The New England Journal of Medicine abstract (doi: 10.1056/NEJMoa2604169; Lilly's medical page lists online-first publication on Sept 29, 2026) reports treatment-regimen weight changes of −17.6%, −23.7%, and −25.0%, versus −3.9% with placebo; the 9 mg and 12 mg differences versus placebo were −19.8 and −21.0 percentage points (both P<0.001). Among 574 participants with knee osteoarthritis, intention-to-treat pain scores (1-10, higher worse) fell 4.1 points at 12 mg and 2.5 points on placebo; the prespecified hybrid estimand was −3.6 versus −1.9. Among 243 participants with obstructive sleep apnea, the intention-to-treat drop in events per hour was 32.1 at 12 mg and 9.6 on placebo. An extension enrolled 532 people, and participants who started on placebo switched to drug, so there is no two-year placebo comparison; ScienceAlert reports 29.9% mean weight loss at 104 weeks in the 12 mg group. About 42% of the top-dose group reported nausea, about 11% stopped for adverse events versus 4.6% on placebo, and serious adverse events were 10.5% versus 5.5%. The trial had no cardiovascular safety endpoint and no head-to-head comparison with semaglutide or tirzepatide.
Links:
- NEJM — Retatrutide for obesity, DOI 10.1056/NEJMoa2604169
- ScienceAlert — Phase 3 retatrutide weight, knee pain, and sleep apnea
Commentary:
This is an unapproved experimental drug, not something to request from a pharmacy because of a news story; people already on a related weight-loss medicine should manage nausea with their clinician and keep resistance training plus adequate protein, rather than raising the dose on their own.
6. China CDC: In week 39, influenza-like illness was 4.4% of outpatient visits, led by influenza, rhinovirus, and SARS-CoV-2 (Public health)
Summary:
The Chinese Center for Disease Control and Prevention posted sentinel surveillance for acute respiratory infections in week 39 of 2026 (Sept 21-27) on Oct 1, excluding Hong Kong, Macao, and Taiwan. Influenza-like illness was 4.4% of outpatient and emergency visits, 5.3% in southern provinces and 3.3% in northern provinces. At 216 hospitals doing multipathogen testing, the top three positives in outpatient influenza-like illness were influenza virus 15.6% (down 3.1 points from the previous week), rhinovirus 14.1% (up 3.4), and SARS-CoV-2 7.2% (down 1.9). Among inpatients with severe acute respiratory infection, the top three were rhinovirus 9.9% (up 3.5), influenza 6.9% (up 0.6), and human metapneumovirus 4.5% (up 0.3). Influenza activity had fallen for two straight weeks and was mainly A(H3N2) and B/Victoria; the south was at a medium level and the north between seasons, with the highest influenza positivity at ages 15-59. Rhinovirus positivity was higher under age 14. No unknown pathogen was found. Most of the country remained at a low level with a small upward fluctuation.
Links:
Commentary:
Over the National Day travel period, priority groups should still follow vaccination guidance for influenza; in the south, and when traveling with children under 14, masks and handwashing in crowds matter, and fever or cough is a reason to mask and seek care if needed.
7. European Union: The first Screening Week runs through Oct 4 and asks adults to know blood pressure, cholesterol, and blood sugar (Public health)
Summary:
The European Commission opened the first EU Screening Week on Sept 28, 2026, running through Oct 4, and on the same day proposed a Council recommendation on cardiovascular health checks, so the week is still underway. The Commission said cardiovascular disease kills about 1.7 million people a year in the EU and costs more than €282 billion, and that addressing high blood pressure, cholesterol, blood sugar, and obesity could prevent up to about 80% of cases. The Safe Hearts Plan aims to cut premature cardiovascular deaths by 25% by 2035. The proposal's 2035 monitoring targets include yearly professional blood-pressure checks for at least 75% of people aged 25-64 and at least 90% of those 65 and older, and cholesterol and blood-sugar checks for at least 65% and at least 80% of those same age groups. A Council recommendation would not legally bind member states.
Links:
- European Commission — EU Screening Week: know your vital numbers
- European Commission — Press release IP/26/1859
Commentary:
People in the EU can ask a clinician this week for blood pressure, lipids, and glucose instead of waiting for a cardiac emergency; the text is not yet a law that every country must carry out.
IV. Evidence & Clarification
8. An FDA advisory panel favored Galleri's benefit-risk balance, the agency has not approved it, and a UK trial's main result did not significantly improve early detection (Evidence)
Summary:
A Reuters follow-up on Oct 2 reviewed the Sept 23 meeting of the FDA Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on GRAIL's Galleri test. The panel voted 7-2, with one abstention, that benefits outweigh risks in adults aged 50 and older; safety was unanimous and effectiveness was 6-4. The FDA is not bound by the vote, has not issued a final decision, and the test is not an FDA-approved product. Reuters reported that a three-year UK trial in asymptomatic adults aged 50-77 did not significantly increase early cancer detection or reduce late-stage diagnoses versus standard screening; full results the company presented in May reported a 26% reduction in stage IV diagnoses across 12 deadly cancers by the third screening round. The FDA's 24-hour summary calls for labeling on false negatives and for people to continue guideline-recommended screening.
Links:
- Reuters via Yahoo Finance — Galleri advisory win and the UK trial
- FDA — Sept. 23, 2026 advisory panel 24-hour summary
Commentary:
Do not replace mammography, cervical screening, colonoscopy, or low-dose lung CT with one out-of-pocket blood test; an advisory vote is not approval, and a negative result does not prove there is no cancer.
Today's Summary
- Diet: Four weeks of optimized meals did not reduce visceral fat on the primary endpoint. In a US cross-section, a higher Mediterranean diet score tracked with lower hypertension prevalence, which is not a treatment effect.
- Training: Upper- and lower-limb activation did not significantly speed a 50 m swim in national-level men. High-intensity intervals changed the gut microbiota of mice and do not translate into a prescription for older adults.
- Public health: Phase 3 retatrutide produced large weight loss in adults with obesity and without diabetes, and it remains experimental. China's week 39 respiratory report showed influenza down and rhinovirus up, while EU Screening Week points to blood pressure, cholesterol, and glucose as the numbers to ask about.
- Evidence: Galleri passed an advisory benefit-risk vote, the UK trial's main result did not show a significant gain in early detection, and existing cancer screening should continue.
Daily Framing:
Today in the sports, health, and nutrition cycle was a day for evidence boundaries and screening numbers: meal kits, diet scores, pre-race activation, and mouse microbiota each stay at their own evidence grade, while the practical checks this week are blood pressure, lipids, glucose, whether an influenza vaccine is due, and the fact that a multi-cancer blood test does not replace screening already in use.
This digest is compiled from real-time search results and is for reference only.